What is Adarza BioSystems?
Adarza BioSystems operates as a premier developer and manufacturer of label-free biosensor assays and instrumentation. By providing high-performance solutions for life science research, drug development, and in-vitro diagnostics, the company addresses critical industry needs for speed, sensitivity, and ease of use. Their proprietary platform enables the rapid identification and quantification of biological target analytes without the requirement for complex chemical labeling or intensive sample processing. This technological edge positions Adarza as a vital player in the advancement of diagnostics for infectious diseases, immunology, and oncology, effectively streamlining workflows for researchers and clinical practitioners alike.
How much funding has Adarza BioSystems raised?
Adarza BioSystems has raised a total of $53.6M across 6 funding rounds:
Angel/Seed
$250K
Series A
$6M
Series B
$5M
Series C
$17M
Series D
$25M
Debt
$350K
Angel/Seed (2013): $250K, investors not publicly disclosed
Series A (2014): $6M led by BioGenerator, Missouri Technology, Serra Capital, St Louis Arch Angels, and Cultivation Capital
Series B (2016): $5M supported by Lewis & Clark Venture Capital and Cultivation Capital
Series C (2017): $17M featuring Rivervest
Series D (2020): $25M backed by 3x5 Partners and Lightchain Capital
Debt (2020): $350K with participation from PPP
Key Investors in Adarza BioSystems
Cultivation Capital
A venture capital firm focused on transformative ideas in life sciences and software, providing capital and network resources to support startups through hyper-growth phases.
BioGenerator
An organization based in St. Louis that fosters innovation by providing both venture capital investment and comprehensive startup support services.
Lewis & Clark Venture Capital
An early-stage venture firm managed by former operators that partners with visionary founders to build iconic B2B software and technology companies.
What's next for Adarza BioSystems?
With the support of this major strategic investment, Adarza BioSystems is well-positioned to accelerate its commercialization efforts and deepen its penetration into the global diagnostics market. The company's focus will likely shift toward scaling its manufacturing capabilities and expanding its portfolio of custom assays to meet the growing demand for high-throughput screening. By leveraging its unique label-free technology, Adarza aims to set new industry standards for dynamic range and sample efficiency, ensuring long-term value creation for its stakeholders and partners in the biotechnology sector.
See full Adarza BioSystems company page
